T. Miller

发表

Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity.

K. Browman, Jill M. Wetter, G. Diaz, 2007, Biochemical pharmacology.

Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.

G. Fox, A. Hancock, S. Gopalakrishnan, 2002, Bioorganic & medicinal chemistry letters.

Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.

G. Fox, A. Hancock, K. Phelan, 2002, Bioorganic & medicinal chemistry letters.

Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.

M. Williams, G. Fox, A. Hancock, 2004, Biochemical pharmacology.

Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 3: 5-Substituted 3-phenyl-1,2,4-oxadiazoles as potent antagonists.

G. Fox, J. Dinges, Henry Q. Zhang, 2004, Bioorganic & medicinal chemistry letters.

G Protein-Dependent Pharmacology of Histamine H3 Receptor Ligands: Evidence for Heterogeneous Active State Receptor Conformations

A. Hancock, S. Buckner, I. Miličić, 2005, Journal of Pharmacology and Experimental Therapeutics.

A robust and high-capacity [(35)S]GTPgammaS binding assay for determining antagonist and inverse agonist pharmacological parameters of histamine H(3) receptor ligands.

J. Brioni, T. Esbenshade, M. Cowart, 2008, Assay and drug development technologies.

Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121.

M. Decker, G. Fox, P. Kroeger, 2006, Life sciences.

Cholecystokinin receptors: relationships among phosphoinositide breakdown, amylase release and receptor affinity in pancreas.

B. Bianchi, A. Nadzan, T. Miller, 1986, The Journal of pharmacology and experimental therapeutics.

Regulation of nociceptin/orphaninFQ secretion by immune cells and functional modulation of interleukin-2

T. Miller, A. Fulford, 2007, Peptides.

Tetrapeptide CCK-A agonists: effect of backbone N-methylations on in vitro and in vivo CCK activity.

L. Bednarz, B. Bianchi, M. Holladay, 1994, Journal of medicinal chemistry.

Synthesis and biological activity of CCK heptapeptide analogues. Effects of conformational constraints and standard modifications on receptor subtype selectivity, functional activity in vitro, and appetite suppression in vivo.

L. Bednarz, B. Bianchi, M. Holladay, 1992, Journal of medicinal chemistry.

Pharmacological and molecular characterization of ATP-sensitive K+ channels in the TE671 human medulloblastoma cell line.

J. Brioni, M. Gopalakrishnan, L. Monteggia, 1999, European journal of pharmacology.

Minimization of potential hERG liability in histamine H3 receptor antagonists

K. Browman, G. Diaz, J. Brioni, 2008, Inflammation Research.

2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist

D. Donnelly-roberts, Jill M. Wetter, M. Nakane, 2005, Neuropharmacology.

In vitro studies on a class of quinoline containing histamine H3 antagonists.

G. Diaz, J. Brioni, Ruth L. Martin, 2010, Bioorganic & medicinal chemistry letters.

Pharmacological properties and pro-cognitive effects of ABT-288, a potent and selective histamine H 3 receptor antagonist

K. Browman, J. Sullivan, J. Brioni, 2012 .

Detection of multiple H3 receptor affinity states utilizing [3H]A‐349821, a novel, selective, non‐imidazole histamine H3 receptor inverse agonist radioligand

A. Hancock, T. Esbenshade, R. Faghih, 2006, British journal of pharmacology.

Differential Activation of Dual Signaling Responses by Human H1 and H2 Histamine Receptors

A. Hancock, T. Esbenshade, T. Miller, 2003, Journal of receptor and signal transduction research.

10 - Selective Cholecystokinin A and Cholecystokinin B/Gastrin Receptor Agonists

B. Bianchi, T. Miller, D. Witte, 1993 .

Cloning and characterization of the monkey histamine H3 receptor isoforms.

J. Brioni, G. Fox, T. Vortherms, 2008, European journal of pharmacology.

Myofibrillar protein synthesis and assembly in satellite cell cultures isolated from skeletal muscle of mice.

R. B. Young, T. Miller, R. Merkel, 1979, Journal of animal science.

Clonal analysis of satellite cells in growing mice.

R. B. Young, T. Miller, R. Merkel, 1978, Journal of animal science.

Fluorescent benzofuran histamine H3 receptor antagonists with sub-nanomolar potency

A. Hancock, T. Esbenshade, M. Cowart, 2006, Inflammation Research.

Pharmacological Properties and Procognitive Effects of ABT-288, a Potent and Selective Histamine H3 Receptor Antagonist

Min Zhang, Min Zhang, K. Browman, 2012, Journal of Pharmacology and Experimental Therapeutics.

Use of the H3 receptor antagonist radioligand [3H]‐A‐349821 to reveal in vivo receptor occupancy of cognition enhancing H3 receptor antagonists

K. Browman, J. Brioni, J. Bauch, 2009, British journal of pharmacology.

Peripheral cholecystokinin type A receptors mediate oxytocin secretion in vivo

B. Bianchi, T. Miller, D. Witte, 1993, Regulatory Peptides.

Use of an inverse agonist radioligand [3H]A-317920 reveals distinct pharmacological profiles of the rat histamine H3 receptor

R. Faghih, T. Miller, D. Witte, 2006, Neuropharmacology.

Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.

K. Browman, Jill M. Wetter, R. Fryer, 2007, Journal of medicinal chemistry.

Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors.

B. Bianchi, A. Nadzan, K. Shiosaki, 1991, Molecular pharmacology.

Effect of central catecholamine depletion on the osmotic and nonosmotic stimulation of vasopressin (antidiuretic hormone) in the rat.

P. Molinoff, R. Schrier, K. M. McDonald, 1979, The Journal of clinical investigation.

In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series.

T. Vortherms, A. Hancock, Marlon D Cowart, 2008, Bioorganic & medicinal chemistry letters.

Pharmacological characterization of a 1,4‐dihydropyridine analogue, 9‐(3,4‐dichlorophenyl)‐3,3,6,6‐tetramethyl‐3,4,6,7,9,10‐hexahydro‐1,8(2H,5H)‐acridinedione (A‐184209) as a novel KATP channel inhibitor

J. Sullivan, M. Gopalakrishnan, S. Buckner, 2003, British journal of pharmacology.

Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.

Jill M. Wetter, M. McPherson, J. Sullivan, 2008, Journal of medicinal chemistry.

trans-3-n-propyl-L-proline is a highly favorable, conformationally restricted replacement for methionine in the C-terminal tetrapeptide of cholecystokinin. Stereoselective synthesis of 3-allyl- and 3-n-propyl-L-proline derivatives from 4-hydroxy-L-proline.

D. Garvey, M. Holladay, A. Nadzan, 1991, Journal of medicinal chemistry.

Double bond isosteres of the peptide bond: synthesis and biological activity of cholecystokinin (CCK) C-terminal hexapeptide analogs.

G. M. Carrera, M. Holladay, M. Stashko, 1993, Bioorganic & medicinal chemistry.

Influence of concentration and rate of intravenous administration on the toxicity of cyclohexanone in beagle dogs.

J. L. Dorner, Leo Martis, T. Miller, 1981, Toxicology and applied pharmacology.

Disposition kinetics of cyclohexanone in beagle dogs.

Leo Martis, T. Miller, T. Darby, 1980, Toxicology and applied pharmacology.

Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).

R. W. Barrett, M. Holladay, A. Nadzan, 1989, Molecular pharmacology.

Characterization of cholecystokinin receptor sites in guinea-pig cortical membranes using [125I]Bolton Hunter-cholecystokinin octapeptide.

T. Miller, C. W. Lin, 1985, The Journal of pharmacology and experimental therapeutics.

A71378: a CCK agonist with high potency and selectivity for CCK-A receptors.

B. Bianchi, M. Holladay, A. Nadzan, 1990, The American journal of physiology.

Development of potent and selective CCK-A receptor agonists from Boc-CCK-4: tetrapeptides containing Lys(N epsilon)-amide residues.

B. Bianchi, M. Stashko, A. Nadzan, 1992, Journal of medicinal chemistry.

Boc-CCK-4 derivatives containing side-chain ureas as potent and selective CCK-a receptor agonists.

B. Bianchi, A. Nadzan, K. Shiosaki, 1991, Journal of medicinal chemistry.

Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.

Jill M. Wetter, A. Hancock, K. Marsh, 2005, Journal of medicinal chemistry.

Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and Selective Histamine H3 Receptor Antagonist with Drug-Like Properties

Thomas R. Miller, Gerard B. Fox, Jill M. Wetter, 2005, Journal of Pharmacology and Experimental Therapeutics.

Cholecystokinin antagonists: (R)-tryptophan-based hybrid antagonists of high affinity and selectivity for CCK-A receptors.

M. Stashko, A. Nadzan, J. Kerwin, 1991, Journal of medicinal chemistry.

Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.

Jill M. Wetter, U. Warrior, M. McPherson, 2008, Journal of medicinal chemistry.

Analysis of Apparent Noncompetitive Responses to Competitive H1-Histamine Receptor Antagonists in Fluorescent Imaging Plate Reader-Based Calcium Assays

A. Hancock, T. Esbenshade, T. Miller, 1999, Journal of biomolecular screening.

Both CCK-A and CCK-B/gastrin receptors are present on rabbit vagus nerve.

T. Miller, C. W. Lin, 1992, The American journal of physiology.

H4 receptor antagonism exhibits anti-nociceptive effects in inflammatory and neuropathic pain models in rats

Jill M. Wetter, J. Brioni, S. Baker, 2010, Pharmacology Biochemistry and Behavior.

An 80-Amino Acid Deletion in the Third Intracellular Loop of a Naturally Occurring Human Histamine H3 Isoform Confers Pharmacological Differences and Constitutive Activity

R. Leurs, G. Bongers, P. van Meer, 2007, Journal of Pharmacology and Experimental Therapeutics.

4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.

Youssef L Bennani, A. Hancock, K. Marsh, 2007, Bioorganic & medicinal chemistry letters.

Two Novel and Selective Nonimidazole Histamine H3 Receptor Antagonists A-304121 and A-317920: I. In Vitro Pharmacological Effects

Michael Williams, Youssef L Bennani, M. Williams, 2003, Journal of Pharmacology and Experimental Therapeutics.

Monitoring cholinergic activity during attentional performance in mice heterozygous for the choline transporter: A model of cholinergic capacity limits

Caitlin S. Mallory, R. Blakely, M. Sarter, 2013, Neuropharmacology.

Characterization of cloned human dopamine D1 receptor-mediated calcium release in 293 cells.

B. Bianchi, M. Stashko, D. Frail, 1995, Molecular pharmacology.

The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.

K. Browman, Jill M. Wetter, A. Hancock, 2008, Journal of medicinal chemistry.

Dynamic Simulation of Human Thermoregulation and Heat Transfer for Spaceflight Applications

Grant C. Bue, David A. Nelson, Thomas R. Miller, 2011 .

Amino acid-derived piperidides as novel CCKB ligands with anxiolytic-like properties

J. Brioni, M. Holladay, M. Stashko, 1995 .

cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.

Jill M. Wetter, J. Brioni, P. Chandran, 2008, Journal of medicinal chemistry.

Rigidified 2-aminopyrimidines as histamine H4 receptor antagonists: effects of substitution about the rigidifying ring.

J. Brioni, T. Esbenshade, M. Cowart, 2010, Bioorganic & medicinal chemistry letters.

ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.

L. Mahan, M. Michaelides, P. Jenner, 1996, The Journal of pharmacology and experimental therapeutics.

Persistent activation of the dopamine D1 receptor contributes to prolonged receptor desensitization: studies with A-77636.

L. Bednarz, P. Curzon, B. Bianchi, 1996, The Journal of pharmacology and experimental therapeutics.

Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy

E. Bush, A. Hancock, P. Jacobson, 2005, Inflammation Research.

In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists.

E. Bush, A. Hancock, P. Jacobson, 2004, Basic & clinical pharmacology & toxicology.

A. Hancock, T. Esbenshade, T. Miller, 2001, European journal of pharmacology.

Isoform dependent differences in histamine H3 receptor constitutive activity revealed by human H3(445) and H3(365) receptors.

J. Brioni, A. Hancock, T. Esbenshade, 2007 .

D-alanine piperazine-amides: novel non-imidazole antagonists of the histamine H3 receptor

G. Fox, A. Hancock, K. Phelan, 2003, Inflammation Research.

Pharmacological Properties and Procognitive Effects of ABT-288, a Potent and Selective Histamine H3 Receptor Antagonist

Min Zhang, K. Browman, J. Sullivan, 2012, Journal of Pharmacology and Experimental Therapeutics.